1. Home
  2. EFOI vs AKTX Comparison

EFOI vs AKTX Comparison

Compare EFOI & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EFOI

Energy Focus Inc.

HOLD

Current Price

$3.08

Market Cap

21.0M

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$7.96

Market Cap

18.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EFOI
AKTX
Founded
1985
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Building Products
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.0M
18.2M
IPO Year
2004
2014

Fundamental Metrics

Financial Performance
Metric
EFOI
AKTX
Price
$3.08
$7.96
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$33.50
AVG Volume (30 Days)
9.3K
50.2K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
43.75
N/A
EPS
N/A
N/A
Revenue
$3,560,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.66
$0.12
52 Week High
$9.84
$29.32

Technical Indicators

Market Signals
Indicator
EFOI
AKTX
Relative Strength Index (RSI) 52.67 35.50
Support Level $2.78 $0.21
Resistance Level $3.37 $15.50
Average True Range (ATR) 0.15 1.21
MACD 0.04 -0.37
Stochastic Oscillator 77.80 1.67

Price Performance

Historical Comparison
EFOI
AKTX

About EFOI Energy Focus Inc.

Energy Focus Inc specializes in designing, developing, manufacturing, and selling energy-efficient lighting systems and controls. It provides LED lighting solutions for both commercial and military maritime markets (MMM). Its core products include robust lighting fixtures and lamps for navy and military applications, Energy Storage Systems (ESS), Uninterruptible Power Supply (UPS), and tubular LED (TLED) lighting products, including battery backup units as well as general commercial and maritime lighting fixtures. The company operates in a single business segment that includes the marketing and sale of commercial and MMM lighting products and controls. The company generates a majority of its revenue from the sales of military maritime products in the United States.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: